Monopar Therapeutics Management
Management criteria checks 2/4
Monopar Therapeutics' CEO is Chandler Robinson, appointed in Dec 2014, has a tenure of 9.67 years. total yearly compensation is $1.78M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth €114.67K. The average tenure of the management team and the board of directors is 5.4 years and 8.5 years respectively.
Key information
Chandler Robinson
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 9.7yrs |
| CEO ownership | 1.5% |
| Management average tenure | 5.4yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$2m | US$580k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$2m | US$550k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$10m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$1m | US$525k | -US$9m |
| Sep 30 2021 | n/a | n/a | -US$9m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$2m | US$504k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | US$541k | US$386k | -US$4m |
| Sep 30 2019 | n/a | n/a | -US$4m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$1m | US$375k | -US$3m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$17m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$401k | US$331k | -US$17m |
Compensation vs Market: Chandler's total compensation ($USD1.78M) is above average for companies of similar size in the German market ($USD531.21K).
Compensation vs Earnings: Chandler's compensation has increased whilst the company is unprofitable.
CEO
Chandler Robinson (40 yo)
9.7yrs
Tenure
US$1,778,655
Compensation
Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.7yrs | US$264.04k | 0.43% $ 32.5k | |
| Co-Founder | 9.7yrs | US$1.78m | 1.51% $ 114.7k | |
| Chief Operating Officer | 3.2yrs | US$911.14k | 1.1% $ 83.3k | |
| CFO, Principal Accounting Officer & Principal Financial Officer | less than a year | no data | no data | |
| Acting Chief Medical Officer | 7.7yrs | no data | no data |
5.4yrs
Average Tenure
53yo
Average Age
Experienced Management: 1IY's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Executive Chairman of the Board | 9.7yrs | US$264.04k | 0.43% $ 32.5k | |
| Co-Founder | 9.7yrs | US$1.78m | 1.51% $ 114.7k | |
| Independent Director | 9.7yrs | US$126.04k | 1.34% $ 101.7k | |
| Independent Director | 7.3yrs | US$136.54k | 0.15% $ 11.6k | |
| Independent Director | 7yrs | US$128.54k | 0.18% $ 13.3k | |
| Director | 1.4yrs | US$848.44k | 0.33% $ 24.8k |
8.5yrs
Average Tenure
65.5yo
Average Age
Experienced Board: 1IY's board of directors are considered experienced (8.5 years average tenure).